Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostic and in vitro diagnostics, today announced it has obtained a CE mark for two new biotherapy monitoring kits; Tocilizumab (anti-IL6R) and Rituximab (anti-CD20) that further expand the Lisa Tracker range.
With these two new additions available in all EU countries, Theradiag now offers a range of seven blood test kits providing comprehensive multi-parameter diagnosis solutions to monitor patients with autoimmune and inflammatory diseases. Rituximab is also used to treat hematological cancers.
Michel Finance, CEO of THERADIAG, says: "These two new monitoring kits expand our theranostic range to cancerology and show that we are on track to meet our roadmap targets. The Lisa Tracker range is a unique diagnostic tool which enables physicians to tailor treatments and optimize patient care. This new CE mark outlines our expert know-how in our lines of innovative proprietary diagnostic products and their sale in international markets."